The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It is, in my opinion, this type of IP evasion by #AVCT which will get them noticed. This is why they are working on B12 assays quietly. Not because it is a huge money spinner (though 200m at 7.2% CAGR is not to sniffed at for a £300m m cap) but because they know as soon as youWhich will detect ‘active’ B12 and enable #AVCT to work around the existing IP (antibody) which is held by Abbott. Blood tests are expensive. Especially in the developing world. The Affimer assay would need less sample preparation than a total vitamin B12 test and cost far less.
Which will detect ‘active’ B12 and enable #AVCT to work around the existing IP (antibody) which is held by Abbott. Blood tests are expensive. Especially in the developing world. The Affimer assay would need less sample preparation than a total vitamin B12 test and cost far less.It is, in my opinion, this type of IP evasion by #AVCT which will get them noticed. This is why they are working on B12 assays quietly. Not because it is a huge money spinner (though 200m at 7.2% CAGR is not to sniffed at for a £300m m cap) but because they know as soon as youStart to evade Abbott’s IP, you’re noticed by their research and sales teams and the Affimer (and it’s wider application) begins to gain traction as they ask what other areas will this small company be seeking to disrupt? Another area they will seek to play in, imo, is Sepsis.1.1Bn USD by 2027, expanding at 9.4% CAGR. Sepsis caused 270k deaths in the US w/2m people contracting. If you can market an Affimer based assay which enables clinicians to differentiate between bacterial and viral infections you enable better antibiotic prescription.Start to evade Abbott’s IP, you’re noticed by their research and sales teams and the Affimer (and it’s wider application) begins to gain traction as they ask what other areas will this small company be seeking to disrupt? Another area they will seek to play in, imo, is Sepsis.
the tread
LFT demand (without covid) was another reason for my 117p purchase of #AVCT yesterday. Most investors are focussed on either AffiDx or AVA6000. However, if one looks beyond these short term drivers to the post-covid LFT potential, I think they will be pleasantly surprised.The size and the scope of the non-Covid LFT market is expansive. All driven by Affimers. Some assays in this area are under licence (such as B12 w/the licence held by Abbott) but others are not. This presents huge opportunity.A B12 efficiency can cause anaemia. The current blood test only measures the amount of B12 is the blood and not whether it is ‘active’ or not. This market is worth around 200m USD and growing at a CAGR of 7.2%. I understand #AVCT to be working on an affimer assay
G-man, if you bothered to read the posts instead of posting your inane comment (commenting on something you have not read!), you would see its not pessimism.
Really, at least try to take some emotion out of stock picking, pessimism, optimism, negativity, positivity.... these words are absolutely irrelevant to deciding why you should hold buy or sell a stock.
And I am sure all be delighted to know I bought a load more this morning at 118p so....well, done me.
Green boxs showing up already. I wonder what pessimism NDN, Eggy, Thirtle, Wyndrum, Coolfree can bring to this thread?
The twitter account you speak off seem to be very well educated, considering they've only just bought in to Avacta and created an account this month.
I'll say it..... its an insider
AVCT - Short term trades or long term investment or both your choice - Thank you Avacta for the long term investment opportunity,
Courtesy of twitter
"I believe this is what RAH is referring to.
@avacta
isn't just a Covid OR Cancer play, it's even more than that. Unbeliveable share price given the mid to long term potential.
https://twitter.com/738Pilot/status/1452906399030202369/photo/1
https://twitter.com/738Pilot/status/1452906399030202369
Thread
See new Tweets
Conversation
RAH
@TheEthicalTout
LFT demand (without covid) was another reason for my 117p purchase of #AVCT yesterday. Most investors are focussed on either AffiDx or AVA6000. However, if one looks beyond these short term drivers to the post-covid LFT potential, I think they will be pleasantly surprised.
8:08 AM · Oct 26, 2021·Twitter for iPad
3
Retweets
1
Quote Tweet
10
Likes
RAH
@TheEthicalTout
·
32m
Replying to
@TheEthicalTout
The size and the scope of the non-Covid LFT market is expansive. All driven by Affimers. Some assays in this area are under licence (such as B12 w/the licence held by Abbott) but others are not. This presents huge opportunity.
Worth checking out
Worth checking out.
Nice to read some new research https://twitter.com/TheEthicalTout